ABDUL KHAN: Open Payments
NPI 1003945221 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$393 in 9 payments from 8 companies in 2025. Trend: 2023 $348 · 2024 $211 · 2025 $393
Food & beverage: $393
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Insulet Corporation | 1 | $38 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Novo Nordisk Inc | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| ABBVIE INC. | 1 | $16 |
Products named: LYBALVI, ABILIFY MAINTENA, Omnipod, NUCALA, COBENFY, Wegovy, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across LA — which companies pay providers there.
